Filing Analysis
Zentalis Pharmaceuticals reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. The company confirmed the election of two Class III directors, the ratification of Ernst & Young LLP as its auditor, and the advisory approval of executive compensation.
📋 Key Facts
- Annual Meeting held on June 16, 2026.
- Quorum represented by 49,453,766 shares (approximately 69.47% of outstanding common stock).
- David Johnson and Jan Skvarka, Ph.D. were elected as Class III Directors.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- Executive compensation was approved on an advisory basis.
Zentalis Pharmaceuticals expanded its Board of Directors from six to seven members and appointed Shannon Campbell as a Class I director and member of the Compensation Committee, effective May 22, 2026.
📋 Key Facts
- Board size increased from 6 to 7 directors
- Shannon Campbell appointed as Class I director effective May 22, 2026
- Campbell appointed to the Compensation Committee
- Annual cash retainer: $45,000 for Board service and $7,500 for Compensation Committee service
- Initial RSU grant of 114,200 shares (0.16% of outstanding shares) granted May 26, 2026, vesting over 3 years
- Future annual RSU grants based on 0.08% of outstanding shares
Zentalis Pharmaceuticals announced positive Phase 1b clinical data for its drug candidate azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer, to be presented at the 2026 ASCO Annual Meeting. The data showed promising efficacy, particularly in the 250 mg intermittent dose cohort, though safety findings included high-grade adverse events and one previously reported patient death.
🚩 Red Flags
- One Grade 5 event (death) due to sepsis was assessed as related to azenosertib by the investigator.
- High treatment discontinuation rate due to adverse events (32.6%).
- High rates of Grade >=3 hematological toxicities, including neutropenia (30.4%) and anemia (19.6%).
📋 Key Facts
- Data from Part 1 of the Phase 1b MUIR trial evaluating azenosertib in combination with paclitaxel in 46 patients with platinum-resistant ovarian cancer (PROC) will be presented at ASCO 2026.
- The overall response rate (ORR) across all cohorts (n=46) was 39.1%, and the clinical benefit rate (CBR) was 58.7%.
- In the optimal 250 mg intermittent dose cohort (n=12), the ORR was 50.0% and the median duration of response was 9.2 months.
- Safety data showed Grade >=3 treatment-related adverse events (TRAEs) of neutropenia (30.4%) and anemia (19.6%).
- 15 patients (32.6%) discontinued treatment due to adverse events, though approximately half were able to continue on azenosertib monotherapy.
Zentalis Pharmaceuticals announced its financial results for the first quarter ended March 31, 2026, and provided a business update. The company also released an updated corporate presentation for upcoming investor and analyst meetings.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were announced on May 12, 2026.
- A new Corporate Presentation dated May 2026 was furnished as Exhibit 99.2.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- The filing was signed by Julie Eastland, President and Chief Executive Officer.
Zentalis Pharmaceuticals announced the dosing of the first patient in its Phase 3 ASPENOVA clinical trial for azenosertib. The trial targets patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC) and is designed to support potential accelerated and full FDA approval.
📋 Key Facts
- The Phase 3 ASPENOVA trial is a randomized, confirmatory clinical trial.
- The trial expects to enroll approximately 420 patients.
- Azenosertib monotherapy (400mg QD 5:2) will be compared against investigator's choice of standard-of-care chemotherapy.
- The trial design incorporates U.S. FDA feedback regarding requirements for accelerated approval and conversion to full approval.
- The primary indication is Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
Zentalis Pharmaceuticals disclosed scientific data presented at the 2026 AACR Annual Meeting regarding its lead candidate, azenosertib. The presentations cover preclinical activity in triple-negative breast cancer and real-world outcomes in Cyclin E1-positive ovarian cancer.
📋 Key Facts
- Presented data at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego (April 17-22, 2026).
- Exhibit 99.2 details preclinical models of WEE1 inhibitor azenosertib in Triple-Negative Breast Cancer (TNBC).
- Exhibit 99.3 analyzes real-world treatment patterns and outcomes for patients with Cyclin E1-positive Ovarian Cancer.
- The disclosures were made under Item 7.01 Regulation FD and are not deemed 'filed' for liability purposes.
Zentalis Pharmaceuticals announced the selection of 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in ovarian cancer following positive interim Phase 2 data. The company plans to initiate a Phase 3 confirmatory trial in Q2 2026 and expects a topline readout for the Phase 2 trial by year-end 2026.
📋 Key Facts
- Selected 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
- The 400mg dose showed a 'meaningful and clearly differentiated response rate' over the 300mg dose with comparable safety.
- Initiation of the confirmatory ASPENOVA Phase 3 clinical trial is expected in Q2 2026.
- Expanded the DENALI Phase 2 trial to include Part 2c, broadening the study to patients previously treated with taxane-containing regimens.
- Company projects existing cash and marketable securities will fund operations into late 2027.
- Topline readout for the registration-intended DENALI Part 2 trial is expected by year-end 2026.
Zentalis Pharmaceuticals announced its full-year 2025 financial results and provided business updates on March 26, 2026. The information was disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results reported for the fiscal year ended December 31, 2025
- Filing includes business updates alongside financial data
- Reported under Item 2.02 (Results of Operations and Financial Condition)
- Press release issued and furnished on March 26, 2026